Adjuvant Nivolumab Demonstrates Reduced Risk of Death or Recurrence Vs Placebo in Stage IIB/C Melanoma
Source: Cancer Network, October 2022
Patients with completely resected stage IIB/C melanoma experienced significant and clinically meaningful improvements in recurrence-free survival following treatment with adjuvant nivolumab compared with placebo.
Nivolumab (Opdivo) produced a statistically significant improvement in recurrence-free survival (RFS) as an adjuvant treatment for patients with completely resected stage IIB or IIC melanoma compared with placebo, according to a press release on the data from the phase 3 CheckMate-76K trial (NCT04099251),
Data from the trial were presented at the 2022 Society for Melanoma Research (SMR) Annual Meeting. In the trial, nivolumab yielded a 58% reduction in risk of death or disease recurrence compared with placebo (HR, 0.42; 95% CI, 0.30-0.59; P <.0001). The 12-month RFS rates were 89% (95% CI, 86%-92%) for those receiving nivolumab and 79% (95% CI, 74%-84%) among those treated with placebo. The RFS benefit of nivolumab was observed across predefined patient subgroups, with patients improving regardless of disease stage and T category. The 12-month RFS rate in the stage IIB group was 93% with nivolumab vs 84% with placebo. In the stage IIC group, nivolumab produced an RFS rate of 84% vs 72% with placebo.